Modalis Therapeutics Corporation (TOKYO: 4883) today announced that its research article titled “Efficient LAMA1 gene activation by epigenome editing as a therapeutic approach for LAMA2-CMD” has been ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback